NPI: 1225088255 · LINVILLE, NC 28646 · General Acute Care Hospital · NPI assigned 05/11/2006
Authorized official LONG, MARY controls 20+ related entities in our dataset. Read more
| Authorized Official | LONG, MARY (SR VP MEDICAL STAFF RELATIONS) |
| Parent Organization | APPALACHIAN REGIONAL HEALTHCARE SYSTEM |
| NPI Enumeration Date | 05/11/2006 |
Other providers sharing the same authorized official: LONG, MARY
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 1,895 | $128K |
| 2019 | 958 | $105K |
| 2020 | 855 | $131K |
| 2021 | 887 | $82K |
| 2022 | 1,187 | $95K |
| 2023 | 1,108 | $115K |
| 2024 | 1,581 | $97K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 2,825 | 2,577 | $413K |
| 41899 | Unlisted procedure, dentoalveolar structures | 111 | 108 | $164K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 921 | 873 | $93K |
| 99284 | Emergency department visit for the evaluation and management, high severity | 153 | 132 | $33K |
| J3490 | Unclassified drugs | 586 | 196 | $13K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 63 | 53 | $9K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1,324 | 1,213 | $8K |
| 80053 | Comprehensive metabolic panel | 482 | 433 | $4K |
| 36415 | Collection of venous blood by venipuncture | 1,093 | 979 | $2K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 87 | 71 | $2K |
| 87634 | 12 | 12 | $1K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 12 | 12 | $1K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 13 | 13 | $965.00 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 29 | 29 | $784.20 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 12 | 12 | $783.11 |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 14 | 12 | $732.85 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 51 | 25 | $544.18 |
| J2704 | Injection, propofol, 10 mg | 18 | 18 | $529.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 86 | 83 | $526.05 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 15 | 15 | $516.46 |
| 71045 | Radiologic examination, chest; single view | 13 | 13 | $495.95 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 14 | 14 | $397.28 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 14 | 14 | $397.28 |
| 81001 | 164 | 147 | $341.61 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 58 | 57 | $325.19 |
| 84443 | Thyroid stimulating hormone (TSH) | 15 | 15 | $284.34 |
| 86803 | 15 | 15 | $249.06 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 78 | 75 | $244.14 |
| 80306 | 14 | 14 | $240.63 | |
| 80061 | Lipid panel | 15 | 15 | $233.80 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 96 | 93 | $189.62 |
| 84439 | 15 | 15 | $157.36 | |
| 83605 | 13 | 12 | $144.07 | |
| 86701 | 14 | 14 | $143.78 | |
| 86592 | 14 | 14 | $74.34 | |
| 80048 | Basic metabolic panel (calcium, ionized) | 12 | 12 | $59.94 |